Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 Accounts Payable

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 (CYCCP) currently reports a accounts payable of $260K as of March 2026. That compares with $110 in the prior-year period — up 224461.4% year over year. Use the charts on this page to explore Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's accounts payable history and peer comparisons.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10's accounts payable increased from $110 to $260K — a 224461.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 reported $260K in accounts payable as of March 2026. That compares with $110 in the prior-year period — up 224461.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $260K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10, and consider following CYCCP for alerts when major investors trade the stock.

Cyclacel Pharmaceuticals- 6% PRF PERPETUAL USD 10 is classified in the Healthcare sector. On accounts payable, it currently shows $260K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYCCP with unrelated industries.